Skip to content

Study on the efficacy and safety of titanium bridge for the adductor type spasmodic dysphonia

Study on the efficacy and safety of titanium bridge for the adductor type spasmodic dysphonia - Study on the efficacy and safety of titanium bridge for the adductor type spasmodic dysphonia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023570
Enrollment
10
Registered
2016-09-01
Start date
2017-02-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adductor type spasmodic dysphonia

Interventions

Thyroplasty type 2 using a titanium bridge

Sponsors

Department of Otolaryngology-Head and Neck SurgerykumamotoUniversityHospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients specialist of Japan Otolaryngology Society certification was diagnosed of Adductor type spasmodic dysphonia 2.Patients effort of utterance or voice interruption of more than 1 year subjective or objective 3.90-year-old following of patients from 20 years of age on consent acquisition date 4.Document consent at the free will of the patients can be obtained

Exclusion criteria

Exclusion criteria: 1.Dysphagia, Laryngeal paralysis or Organic lesion in the vocal cord 2.Patients with serious complications 3.Patients with a history of mental illness, mental disorders, intellectual disability, alcoholism and drug abuse in need of such treatment. 4.Hypersensitivity history with respect to pure titanium

Design outcomes

Primary

MeasureTime frame
The amount of change before and after surgery of VHI-10 Preoperative and postoperative 13 weeks

Countries

Japan

Contacts

Public ContactKouhei Nishimoto

kumamotoUniversityHospital Department of Otolaryngology-Head and Neck Surgery

jibika-ikyoku@kumamoto-u.ac.jp096-373-5255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026